Immune thrombocytopenia (ITP) - Pipeline Insight, 2024

This “Immune thrombocytopenia - Pipeline Insight, 2024,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Immune thrombocytopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Immune thrombocytopenia Understanding

Immune thrombocytopenia: Overview

Immune thrombocytopenia (ITP), formerly known as Idiopathic thrombocytopenic purpura is an autoimmune bleeding disorder. The disease is characterized by abnormally low levels of blood cells called platelets. ITP manifests as a bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae). The diagnosis of ITP is made by excluding other causes of thrombocytopenia along with blood tests. Treatment for ITP is based on goals to prevent bleeding and stabilize as well as improvement in platelet count. Corticosteroid drugs like prednisone, dexamethasone, and methylprednisolone is usually the mainstay of first line therapy. In 2008, the FDA approved Nplate and Promacta to treat both children and adults with ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Immune thrombocytopenia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune thrombocytopenia pipeline landscape is provided which includes the disease overview and Immune thrombocytopenia treatment guidelines. The assessment part of the report embraces, in depth Immune thrombocytopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune thrombocytopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Immune thrombocytopenia R&D. The therapies under development are focused on novel approaches to treat/improve Immune thrombocytopenia.

Immune thrombocytopenia Emerging Drugs Chapters

This segment of the Immune thrombocytopenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Immune thrombocytopenia Emerging Drugs

Rozanolixizumab (UCB7665): UCBRozanolixizumab humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P). By blocking IgG recycling, this subcutaneously infused monoclonal antibody aims to improve the course of immunoglobulin G (IgG)-mediated autoimmune diseases by reducing pathogenic autoantibody levels. Rozanolixizumab, an investigational monoclonal antibody, was granted orphan drug designation for the treatment of ITP by the US Food and Drug Administration on 30 April 2018 and by the European Commission on 11 January 2019. The drug is in Phase III clinical studies for the treatment of idiopathic thrombocytopenic purpura, myasthenia gravis and in Phase II clinical studies for chronic inflammatory demyelinating polyradiculoneuropathy and encephalitis.

Efgartigimod: ar GEN-XEfgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. The drug is in registration phase for myasthenia gravis and in Phase III clinical studies for Primary Immune Thrombocytopenia (ITP), chronic inflammatory demyelinating polyradiculoneuropathy, and Pemphigusvulgaris.

Immune thrombocytopenia: Therapeutic Assessment

This segment of the report provides insights about the different Immune thrombocytopenia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Immune thrombocytopenia

There are approx. 30+ key companies which are developing the therapies for Immune thrombocytopenia. The companies which have their Immune thrombocytopenia drug candidates in the most advanced stage, i.e. Phase III include, UCB.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Immune thrombocytopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Immune thrombocytopenia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immune thrombocytopenia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immune thrombocytopenia drugs.

Immune thrombocytopenia Report Insights

• Immune thrombocytopenia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Immune thrombocytopenia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Immune thrombocytopenia drugs?
• How many Immune thrombocytopenia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Immune thrombocytopenia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Immune thrombocytopenia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Immune thrombocytopenia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• UCB
• arGEN-X
• HanAll Biopharma/Immunovant
• Momenta Pharmaceuticals
• Principia Biopharma
• Hutchison MediPharma
• Cour Pharmaceutical Development

Key Products

• Rozanolixizumab (UCB7665)
• Efgartigimod
• Batoclimab
• M 254
• Rilzabrutinib
• HMPL 523
• CNP-105

This product will be delivered within 1-3 business days.